GENFIT’s Lead Drug, Elafibranor, Moves into Phase 3 for Primary Biliary Cholangitis Following FDA Breakthrough Therapy Designation

GENFIT’s Lead Drug, Elafibranor, Moves into Phase 3 for Primary Biliary Cholangitis Following FDA Breakthrough Therapy Designation

GENFIT announced the FDA has granted Breakthrough Therapy Designation to its lead product candidate elafibranor for the treatment of Primary Biliary Cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA). Breakthrough Therapy Designation...

Pin It on Pinterest